Search
Arvinas Inc
ARVNAdd to Watchlist
9.180USD
+0.210+2.34%
Market hours （ET）Quotes delayed by 15 min
592.11MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Arvinas Inc is 7.18, ranking 303 out of 387 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 21.00 and a low of 6.00.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
14.286
Target Price
+59.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Arvinas Inc
ARVN
17
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Arvinas Inc's expected revenue for the next quarter?
Arvinas Inc's expected revenue is 24.50M.
What is Arvinas Inc's price target?
Analysts forecast that Arvinas Inc's price target is USD 14.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 6.00.
How have Arvinas IncARVN's recent earnings per share performed?
The market expectation was USD 2.61, while Arvinas IncARVN's earnings per share (EPS) for the previous quarter was USD -0.90. EPS for the next quarter is expected at USD -0.83.
What is the analyst rating for Arvinas Inc?
Based on the ratings of Arvinas Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.